Amylyx Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Amylyx Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 4 completed early-phase tilt top decile by trial count

Amylyx Pharmaceuticals: 9 sponsored US clinical trials, 1 recruiting.

Amylyx Pharmaceuticals sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Amyotrophic Lateral Sclerosis, with 3 trials.

Top-decile sponsor footprint

Amylyx Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 1

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165
ACTIVE NOT RECRUITING Phase 3

Avexitide for Treatment of Post-Bariatric Hypoglycemia

NCT06747468
ACTIVE NOT RECRUITING Phase 2

AMX0035 and Progressive Supranuclear Palsy

NCT06122662
ACTIVE NOT RECRUITING Phase 2

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
ACTIVE NOT RECRUITING Phase 3

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

NCT05021536
COMPLETED Phase 2

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04516096
COMPLETED Phase 2

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

NCT03533257
COMPLETED Phase 2

Open Label Extension Study of AMX0035 in Patients With ALS

NCT03488524
COMPLETED Phase 2

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03127514

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6
Phase 3 2

Therapeutic Areas

Amyotrophic Lateral Sclerosis 3
ALS 2
Atypical Parkinsonism 1
Wolfram Syndrome 1
PSP 1
Neurodegenerative Diseases 1
Post-Bariatric Hypoglycemia 1
Progressive Supranuclear Palsy 1
Alzheimer Disease 1

What is open in the Amylyx Pharmaceuticals pipeline

1 recruiting of 9 indexed (11% open); 4 completed (44%).

Phase mix: 2 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Amyotrophic Lateral Sclerosis (3 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Amylyx Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Amylyx Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Amylyx Pharmaceuticals4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAprea Therapeutics
Amylyx Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Amylyx Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Amylyx Pharmaceuticals page

9 registered trials is a research-attention snapshot, not an endorsement of Amylyx Pharmaceuticals or any single study.

  • 1 of Amylyx Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Amyotrophic Lateral Sclerosis is the condition Amylyx Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Amyotrophic Lateral Sclerosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Amylyx Pharmaceuticals pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.